Stoke Therapeutics and Biogen Present Long-Term Clinical Data that Support the Disease-Modifying Potential of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
Biogen Inc BIIB
News
Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)
LEQEMBI IQLIK®(lecanemab-irmb) Autoinjector for Initiation of Therapy Now Available in the U.S. for Early Alzheimer's Disease
Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
LEQEMBI® Real-World LEADER Study Presented at AAIC® 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of Treatment
Eisai, Biogen Get FDA Approval for Treatment for Early Alzheimer's Disease
FDA Approves LEQEMBI IQLIK® (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's Disease
LEQEMBI® Subcutaneous Autoinjector Clinical Data Supports Similar Efficacy and Safety to IV Formulation in Early Alzheimer's Disease Presented at the Alzheimer's Association International Conference® (AAIC®) 2026
Biogen Gets FDA Breakthrough Designation for Spinraza Successor Salanersen
These Alzheimer's drugs were supposed to revolutionize the way we fight the disease. The reality is more complicated.
With Zepbound approved for sleep apnea, Lilly spends up to $7.8 billion for a company with a narcolepsy drug
Biogen will acquire a drug company for $5.6 billion to expand work in kidney diseases
Biogen Gets FDA OK of High-Dose Spinraza Regimen
Biogen Gets FDA Breakthrough Designation for Litifilimab in CLE
Walmart was too late for a Nasdaq-100 spot - but these 6 stocks made the cut
Novo Nordisk's oral GLP-1 drug didn't work on Alzheimer's as hoped, but don't call it a failure
Biogen Gets CHMP Backing for Higher-Dose Spinraza
Biogen, Eisai Get FDA Approval for Injectable Alzheimer's Treatment
United States